Sunday, November 15, 2026 | 06:44 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Gland Pharma

Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%

Divi's Labs, Laurus Labs, Sai Life Sciences and Glenmark Pharma quoted at their respective record highs in Monday's trade.

Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%
Updated On : 09 Nov 2026 | 12:23 PM IST

Gland Pharma Q2FY27 results: Net profit rises 58% to ₹290.75 crore

Gland Pharma on Friday posted a 58.29 per cent rise in consolidated net profit to Rs 290.75 crore in the September quarter, driven by strong execution across businesses. The company had reported a net profit of Rs 183.68 crore in the year-ago period. The pharmaceutical company's revenue from operations rose to Rs 1,833.58 crore in the quarter under review from Rs 1,486.87 crore a year ago, the company said in a regulatory filing. Total expenses also rose to Rs 1,471.69 crore in the July-September period from Rs 1,287.12 crore a year earlier, it said. The company launched four molecules -- Sugammadex, Erythromycin, Fluorouracil and Atropine sulfate -- in the US this quarter, it said in a release. Gland Pharma Executive Chairman Srinivas Sadu said, "We delivered another quarter of strong growth...driven by strong execution across our businesses. Our CDMO business grew 31 per cent year-on-year, supported by expanding customer engagements, strategic partnerships and a robust opportuni

Gland Pharma Q2FY27 results: Net profit rises 58% to ₹290.75 crore
Updated On : 06 Nov 2026 | 8:17 PM IST

Stocks to watch: Airtel, Titan, Blue Dart, Gland Pharma, ONGC, Britannia

Hindalco Industries, Honasa Consumer, Siemens, Aster DM Quality Care, Blue Dart Express, Bombay Dyeing & Manufacturing Company are among the companies to report Q2FY27 results.

Stocks to watch: Airtel, Titan, Blue Dart, Gland Pharma, ONGC, Britannia
Updated On : 06 Nov 2026 | 8:05 AM IST

Pharma shares shine: Divi's, Laurus hit new highs; zoom up to 91% in FY27

India's CRDMO sector growth rebounded to 19% YoY in Q1FY27 versus just 9% YoY in the March 2026 quarter, marking the highest growth level since the December 2024 quarter, notes Jefferies.

Pharma shares shine: Divi's, Laurus hit new highs; zoom up to 91% in FY27
Updated On : 26 Aug 2026 | 11:22 AM IST

Gland Pharma rallies 12%, stock hits 4-year high post Q1 results

Gland Pharma Share: The market price of Gland Pharma hit a high of ₹2,989.2 in intra-day deals on Tuesday. The stock bounced back 90 per cent from its 52-week low of ₹1,575 touched on March 16, 2026.

Gland Pharma rallies 12%, stock hits 4-year high post Q1 results
Updated On : 11 Aug 2026 | 11:06 AM IST

Mukul Agrawal portfolio: Neuland Labs soars 10%, hits new high; here's why

In the past six months, the stock price of Neuland Labs outperformed the market by surging 68 per cent, as compared to 6 per cent decline in the BSE Sensex.

Mukul Agrawal portfolio: Neuland Labs soars 10%, hits new high; here's why
Updated On : 06 Aug 2026 | 10:38 AM IST

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan
Updated On : 22 Jul 2026 | 10:19 AM IST

Gland Pharma shares jump 16% to 52-week high on Q4; analysts retain 'Buy'

Sentiment was further buoyed by bullish brokerage commentary, with Elara Capital and Motilal Oswal Financial Services retaining Buy calls on Gland Pharma, citing strong earnings

Gland Pharma shares jump 16% to 52-week high on Q4; analysts retain 'Buy'
Updated On : 18 May 2026 | 12:36 PM IST

Gland Pharma rises 5%, hits 1-month high on USFDA nod to eye-allergy drug

Gland Pharma jumped 4.80 per cent to ₹1,790.40, the highest level since December 3, 2025, on the National Stock Exchange.

Gland Pharma rises 5%, hits 1-month high on USFDA nod to eye-allergy drug
Updated On : 08 Jan 2026 | 11:05 AM IST

Stocks to Watch today, Jan 8: Cipla, Tata Steel, Meesho, Shriram Fin, MCX

Stocks to Watch today, January 8, 2026: From Tata Steel to Cipla, here is a list of stocks that will be on investors' radar

Stocks to Watch today, Jan 8: Cipla, Tata Steel, Meesho, Shriram Fin, MCX
Updated On : 08 Jan 2026 | 8:05 AM IST

Stocks to Watch today, Nov 4: Bharti Airtel, Titan, Hero MotoCorp, Cipla

Stocks to Watch today, November 4, 2025: From Bharti Airtel, Hero MotoCorp, Titan Company, and Power Grid, here is a list of stocks that will be in focus today

Stocks to Watch today, Nov 4: Bharti Airtel, Titan, Hero MotoCorp, Cipla
Updated On : 04 Nov 2025 | 8:18 AM IST

Gland Pharma Q2 results: Profit rises 12% on recovery at Europe's Cenexi

The consolidated net profit rose to 1.84 billion rupees (nearly $21 million) for the quarter ended September 30 from 1.64 billion rupees a year earlier

Gland Pharma Q2 results: Profit rises 12% on recovery at Europe's Cenexi
Updated On : 03 Nov 2025 | 5:28 PM IST

Jefferies upbeat on India CRDMO; initiates Buy on Cohance; upgrades Divi's

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details

Jefferies upbeat on India CRDMO; initiates Buy on Cohance; upgrades Divi's
Updated On : 25 Aug 2025 | 12:22 PM IST

Gland Pharma shares jump 6% post Q1 show; should you buy, sell or hold?

The pharma company's profit after tax (PAT) for the quarter ended June 30, 2025, stood at ₹215 crore, up 50 per cent from ₹143 crore reported in the corresponding quarter of the previous fiscal year.

Gland Pharma shares jump 6% post Q1 show; should you buy, sell or hold?
Updated On : 06 Aug 2025 | 11:47 AM IST

Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround

Sequentially, the company's net profit rose by 15 per cent, and revenue increased by 6 per cent

Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround
Updated On : 05 Aug 2025 | 11:20 PM IST

Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?
Updated On : 22 Jul 2025 | 11:43 AM IST

Gland Pharma shares rise on GMP nod for Telangana manufacturing unit

Gland Pharma shares rose 2 per cent after it received a GMP certification from the Danish Medicines Agency for its Telangana plant

Gland Pharma shares rise on GMP nod for Telangana manufacturing unit
Updated On : 14 Jul 2025 | 10:29 AM IST

Glenmark, Laurus Lab: Will Trump's 200% tariff threat derail pharma stocks?

Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.

Glenmark, Laurus Lab: Will Trump's 200% tariff threat derail pharma stocks?
Updated On : 09 Jul 2025 | 10:34 AM IST

Gland Pharma jumps 3% in trade; here's what is boosting investor interest

Gland Pharma share price rose 3 per cent logging an intraday high at ₹1,800 per share; here's why

Gland Pharma jumps 3% in trade; here's what is boosting investor interest
Updated On : 24 Jun 2025 | 12:29 PM IST

Breakout stocks: Nifty Pharma, Biocon, Cipla break over 200-DMA; what next?

The Nifty Pharma index and select shares such as Biocon, Cipla, Zydus Life and Gland Pharma were trading above the respective 200-DMAs after more than 2 months; show technical charts.

Breakout stocks: Nifty Pharma, Biocon, Cipla break over 200-DMA; what next?
Updated On : 12 Jun 2025 | 1:05 PM IST